Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto

The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal,...

Full description

Saved in:
Bibliographic Details
Main Authors Hagen Eric J, Louks David H, Hanko Jason A, Daugs Edward D
Format Patent
LanguageEnglish
Published 19.12.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
Bibliography:Application Number: US201514957962